Drugs / L-TIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05878028 | Sep 2022 → Sep 2025 | non-small cell lung carcinoma | Quanli Gao | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05878028 ↗ |
| Modality | Cell therapy | “L-TIL cells infusion” NCT05878028 ↗ |
| Route | Intravenous | “L-TIL cells, （3-10）x10\^9/m2, ivgtt, d14, Q3W for 4 or 6 cycles” NCT05878028 ↗ |